Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Shares Outstanding (2016 - 2025)

VYNE Therapeutics (VYNE) has disclosed Shares Outstanding for 4 consecutive years, with $24.4 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Shares Outstanding rose 5.03% year-over-year to $24.4 million, compared with a TTM value of $24.4 million through Dec 2019, up 5.03%, and an annual FY2019 reading of $24.4 million, up 5.03% over the prior year.
  • Shares Outstanding was $24.4 million for Q4 2019 at VYNE Therapeutics, up from $24.0 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $24.4 million in Q4 2019 and bottomed at $5.3 million in Q4 2016.
  • Average Shares Outstanding over 4 years is $19.9 million, with a median of $23.2 million recorded in 2018.
  • The sharpest move saw Shares Outstanding increased 0.35% in 2017, then surged 338.48% in 2018.
  • Year by year, Shares Outstanding stood at $5.3 million in 2016, then increased by 0.35% to $5.3 million in 2017, then soared by 338.48% to $23.2 million in 2018, then rose by 5.03% to $24.4 million in 2019.
  • Business Quant data shows Shares Outstanding for VYNE at $24.4 million in Q4 2019, $24.0 million in Q3 2019, and $23.9 million in Q2 2019.